Lenvatinib plus anti-PD-1 therapy represents a feasible conversion resection strategy for patients with initially unresectable hepatocellular carcinoma: A retrospective study

PURPOSE: We aimed to investigate the feasibility of lenvatinib plus anti-PD-1 therapy as a conversion therapy for initially unresectable hepatocellular carcinoma (HCC). METHODS: Patients with initially unresectable HCC who received combined lenvatinib and anti-PD-1 antibody between May 2020 and Jan...

Descripción completa

Detalles Bibliográficos
Autores principales: Yi, Yong, Sun, Bao-Ye, Weng, Jia-Lei, Zhou, Cheng, Zhou, Chen-Hao, Cai, Ming-Hao, Zhang, Jing-Yun, Gao, Hong, Sun, Jian, Zhou, Jian, Fan, Jia, Ren, Ning, Qiu, Shuang-Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9731103/
https://www.ncbi.nlm.nih.gov/pubmed/36505772
http://dx.doi.org/10.3389/fonc.2022.1046584

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9731103/
https://www.ncbi.nlm.nih.gov/pubmed/36505772
http://dx.doi.org/10.3389/fonc.2022.1046584

Ejemplares similares